Abstract
Introduction Alzheimer’s disease (AD) is the most common cause of dementia. Non-invasive, affordable, and largely available biomarkers that are able to identify patients at a prodromal stage of AD are becoming essential, especially in the context of new disease-modifying therapies. Mild cognitive impairment (MCI) is a critical stage preceding dementia, but not all MCI patients will progress to AD. This study explores the potential of non-invasive magnetoencephalography (MEG) to predict future cognitive decline from MCI to AD dementia.
Methods We analyzed resting state MEG data from the BioFIND dataset including 117 MCI patients, of whom 64 progressed to AD dementia (AD progression) while 53 remained stable (stable MCI) using multivariate spectral analyses. The patients were followed-up between 2009 and 2018. Receiver operating characteristic curves obtained via logistic regression models were used to quantify separation of patients progressing to AD dementia from stable MCI.
Results MEG beta power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group compared to stable MCI, indicative of future cognitive decline. Logistic regression models showed that MEG beta power outperformed conventional metrics like the Mini Mental Status Examination (MMSE) score and structural brain measures in predicting progression to AD dementia (AUC 0.81 vs 0.71 and AUC 0.81 vs 0.75, respectively). The combination of age, education, MMSE, MEG beta power and Hippocampal volume/Total grey matter ratio achieved a 0.83 AUC, 78% sensitivity and 76% specificity. Spectral covariance matrices analyzed with Riemannian methods exhibited significant differences between groups across a wider range of frequencies than spectral power.
Discussion These findings highlight the potential of spectral power and covariance as robust non-invasive electrophysiological biomarkers to predict MCI progression that complement other diagnostic measures, including cognitive scores, structural magnetic resonance imaging (MRI) and biological biomarkers.
Competing Interest Statement
P.G., J.F.H. & D.E. are full-time employees of F. Hoffmann - La Roche Ltd.
Funding Statement
This work was supported by: EU JNPD (MR/P502017/1), MRC (SUAG/046 G101400) and Fondation pour la Recherche Médicale (grant FDM202106013579).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Local Ethics committee of the MRC Cognition & Brain Sciences Unit at the University of Cambridge, and of the Laboratory of Cognitive and Computational Neuroscience at the Centre for Biomedical Technology, Madrid, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
BioFIND is a controlled access repository and access is institutionally granted.
